Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Clin Infect Dis. 2022 Aug 24;75(1):e525-e528. doi: 10.1093/cid/ciac199.

Abstract

ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183.

Keywords: COVID-19; SARS-CoV-2; molnupiravir; nonplasma; pharmacokinetics.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Cytidine / analogs & derivatives
  • Humans
  • Hydroxylamines
  • Nucleosides
  • Parents
  • Prodrugs* / therapeutic use
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Hydroxylamines
  • Nucleosides
  • Prodrugs
  • Cytidine
  • N(4)-hydroxycytidine
  • molnupiravir

Associated data

  • ClinicalTrials.gov/NCT04746183